» Articles » PMID: 35351872

Adiponectin Receptor Agonist Ameliorates Cardiac Lipotoxicity Via Enhancing Ceramide Metabolism in Type 2 Diabetic Mice

Overview
Journal Cell Death Dis
Date 2022 Mar 30
PMID 35351872
Authors
Affiliations
Soon will be listed here.
Abstract

Accumulation of lipids and their metabolites induces lipotoxicity in diabetic cardiomyopathy. Lowering ceramide concentration could reduce the impact of metabolic damage to target organs. Adiponectin improves lipotoxicity through its receptors (AdiopRs), which have sequence homology with ceramidase enzymes. Therefore, cardioprotective role of AdipoR agonism by AdipoRon was investigated. Sixteen-week-old male db/m and db/db mice were fed a diet containing AdipoRon for four weeks. Phenotypic and metabolic profiles with associated cellular signaling pathways involved in lipid metabolism were investigated in the mice heart and human cardiomyocytes to establish treatment effect of AdipoRon. AdipoRon ameliorated insulin resistance, fibrosis, M1-dominant inflammation, and apoptosis in association with reduced accumulations of free fatty acid, triglycerides, and TLR4-related ceramide in the heart. This resulted in overall reduction in the level of oxidative stress which ameliorated cardiac hypertrophy and its function. AdipoRon increased the expression of AdipoR1 and AdipoR2 via pAMPK/FoxO1-induced Akt phosphorylation resulting from a decrease in PP2A level. It also increased acid ceramidase activity which reduced ceramide and increased sphingosine-1 phosphate levels in the heart of db/db mice and cultured human cardiomyocytes. Consistent upregulation of AdipoRs and their downstream regulatory pathways involving pAMPK/PPARα/PGC-1α levels led to lipid metabolism enhancement, thereby improving lipotoxicity-induced peroxisome biogenesis and oxidative stress. AdipoRon might control oxidative stress, inflammation, and apoptosis in the heart through increased AdipoR expression, acid ceramidase activity, and activation of AMPK-PPARα/PGC-1α and related downstream pathways, collectively improving cardiac lipid metabolism, hypertrophy, and functional parameters.

Citing Articles

Exercise in Diabetic Cardiomyopathy: Its Protective Effects and Molecular Mechanism.

Chen H, Guo L Int J Mol Sci. 2025; 26(4).

PMID: 40003929 PMC: 11855851. DOI: 10.3390/ijms26041465.


Changes in insulin, adiponectin and lipid concentrations with age are associated with frailty and reduced quality of life in dogs.

McKenzie B, Peloquin M, Graves J, Chen F, Tovar A, Carttar T Sci Rep. 2025; 15(1):5380.

PMID: 39948141 PMC: 11825863. DOI: 10.1038/s41598-025-89923-z.


Oral Administration of the Adiponectin Receptor 1 Agonistic Dipeptide Tyr-Pro Prevents Hyperglycemia in Spontaneously Diabetic Torii Rats.

Nakamura S, Asaba S, Tanaka M, Matsui T ACS Omega. 2025; 10(1):1411-1418.

PMID: 39829448 PMC: 11740145. DOI: 10.1021/acsomega.4c09030.


Striking Cardioprotective Effects of an Adiponectin Receptor Agonist in an Aged Mouse Model of Duchenne Muscular Dystrophy.

Abou-Samra M, Dubuisson N, Marino A, Selvais C, Romain V, Davis-Lopez de Carrizosa M Antioxidants (Basel). 2025; 13(12.

PMID: 39765879 PMC: 11674016. DOI: 10.3390/antiox13121551.


Peroxisome proliferator‑activated receptor γ coactivator‑1α in heart disease (Review).

Sun S, Guo H, Chen G, Zhang H, Zhang Z, Wang X Mol Med Rep. 2024; 31(1).

PMID: 39513608 PMC: 11551696. DOI: 10.3892/mmr.2024.13382.


References
1.
Summers S . Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006; 45(1):42-72. DOI: 10.1016/j.plipres.2005.11.002. View

2.
Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S . Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004; 279(29):30817-22. DOI: 10.1074/jbc.M402367200. View

3.
Di Paola M, Cocco T, Lorusso M . Ceramide interaction with the respiratory chain of heart mitochondria. Biochemistry. 2000; 39(22):6660-8. DOI: 10.1021/bi9924415. View

4.
Banerjee S, Peterson L . Myocardial metabolism and cardiac performance in obesity and insulin resistance. Curr Cardiol Rep. 2007; 9(2):143-9. DOI: 10.1007/BF02938341. View

5.
Chen B, Ma Y, Meng R, Xiong Z, Wang H, Zeng J . Activation of AMPK inhibits cardiomyocyte hypertrophy by modulating of the FOXO1/MuRF1 signaling pathway in vitro. Acta Pharmacol Sin. 2010; 31(7):798-804. PMC: 4007721. DOI: 10.1038/aps.2010.73. View